氨磺必利治疗精神分裂症疗效以及安全性研究

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (10): 1152-1157.

氨磺必利治疗精神分裂症疗效以及安全性研究

周勇¹，陈雪芳¹，黄汉津²

¹浙江省嘉兴市康慈医院精神科，桐乡 314500，浙江；²浙江省温州市温州医科大学第二临床医院神经内科，温州 325001，浙江

收稿日期:2017-01-16 修回日期:2017-04-03 出版日期:2017-10-26 发布日期:2017-11-13
通讯作者: 黄汉津，男，主任医师，硕士研究生导师，研究方向：临床精神病学。 E-mail:hhj@wmu.edu.cn
作者简介:周勇，男，硕士研究生，副主任医师，研究方向: 临床精神病学。 Tel：18657335738 E-mail:zhouyong19831124@sina.com
基金资助:
嘉兴市科技计划项目(2012AY1805)

Efficacy and safety of amisulpride for schizophrenia

ZHOU Yong ¹, Chen Xuefang¹, HUANG Hanjin²

¹ Department of Geriatrics, Kangci Hospital of Jiaxing, Tongxiang 314500, Zhejiang, China; ² Department of Neurology, the Second Clinical Hospital of Wenzhou Medical University, Wenzhou 325001, Zhejiang, China

Received:2017-01-16 Revised:2017-04-03 Online:2017-10-26 Published:2017-11-13

摘要/Abstract

摘要：

目的: 本研究主要探讨氨磺必利对照利培酮治疗精神分裂症的疗效以及安全性。方法: 共90例精神分裂症患者被随机分入氨磺必利组和利培酮组，各45例。在治疗前以及治疗后第2、4、8周末，使用阳性和阴性症状量表（positive and negative syndrome scale，PANSS）对病例精神症状进行评定，病情的严重程度采用临床大体疗效量表疾病严重程度（clinical global impressionsseverity of illness scale，CGI-S）评定，通过比较量表评分前后变化来评价疗效；副反应量表（TESS）评定不良反应的发生率以评价安全性。结果: 两组在各时点PANSS评分的总分和各因子分相比基线时均有显著性降低，且差异有统计学意义（P<0.05）；与利培酮相比，氨磺必利组阴性症状评分明显下降，差异有统计学意义（P<0.05）；两组间PANSS评分的总分、阳性症状和精神病理症状分在各时点比较差异无统计学意义（P>0.05）。与利培酮组相比，氨磺必利组CGI-S评分较基线时均有显著降低，差异有统计学意义(P<0.01)，两组间CGI-S评分比较差异无统计学意义（P>0.05）。至研究结束，两组都没有发生严重的不良反应，经统计学检验，两组各种不良反应的发生率差异无统计学意义（P>0.05）。结论: 氨磺必利治疗精神分裂症疗效明显，能显著改善患者的阳性症状、阴性症状、一般病理症状，其疗效与利培酮相当，在改善阴性症状上优于利培酮。氨磺必利治疗精神分裂症耐受性好，未发生严重的不良反应。

关键词: 精神分裂症, 氨磺必利, 利培酮

Abstract:

AIM: To explore the efficacy and safety of amisulpride in treating patients with schizophrenia. METHODS: Ninety patients with schizophrenia were randomly divided into the experimental group (received amisulpride) and the control group (received risperidone) with forty-five cases in each group. The Positive and Negative Syndrome Scale (PANSS) was used to assess the patients' mental symptoms and the Clinical Global Impressions-Severity of Illness Scale (CGI-S) for the degree of severity; the efficacy was assessed through the changes of scores, the improvement rate and effective rate of symptoms. The Treatment Emergent Symptom Scale (TESS) was assessed to evaluate the adverse reactions. All scales were assessed before treatment and at the 2nd, 4th, 8th weekend after treatment. RESULTS:The scores of PANSS and all its factor scores at every time interval were significantly lower than those at baseline (P<0.05). The scores of negative symptoms in the experimental group were much lower than those in the control group at the 2nd, 4th, 8th weekend after treatment (P<0.05). There's no difference in total scores of PANSS, scores of positive symptoms and psychopathological symptoms between the two groups at every time interval (P>0.05). Scores of CGI-S in the experimental group was obviously lower than those at baseline in comparison with the control group (P<0.01). There's no difference in scores of CGI-S between the two groups (P>0.05). Both of two groups presents no severe adverse reactions after treatment, and no significant difference was observed between the two groups either (P>0.05). CONCLUSION: Both amisulpride and risperidone can obviously improve patiens' positive, negative and psychopathological symptoms. However, the efficacy on negative symptoms of amisulpride is better than that of risperidone. Amisulpride also exhibit better tolerance with no severe adverse reaction in treating schizophrenia.

Key words: schizophrenia, amisulpride, risperidone

中图分类号:

R749

周勇，陈雪芳，黄汉津. 氨磺必利治疗精神分裂症疗效以及安全性研究[J]. 中国临床药理学与治疗学, 2017, 22(10): 1152-1157.

ZHOU Yong, Chen Xuefang, HUANG Hanjin. Efficacy and safety of amisulpride for schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1152-1157.

参考文献

［1］江开达.精神病学高级教程［M］//赵靖平,精神分裂症.北京：人民军医出版社，2009：125-143.
［2］Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia. "Just the facts" What we know in 2008. 2. Epidemiology and etiology［J］. Schizophr Res, 2008,102(1/2/3):1-18.
［3］Moller HJ, van Praag HM, Aufdembrinke B,et al. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia［J］. Psychopharmacology (Berl), 1994, 115(1/2):221-228.
［4］Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity［J］. J Pharmacol Exp Ther, 1997, 280(1):73-82.
［5］Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia［J］. Drugs, 2001,61(14):2123-2150.
［6］Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride,an unusual'atypical' antipsychotic: a meta-analysis of randomized controlled trials［J］. Am J Psychiatry, 2002, 159(2):180-190.
［7］江开达，精神病学高级教程［M］//司天梅, 精神药物治疗.北京：人民军医出版社，2009：280-296.
［8］Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010:a systematic analysis for the Global Burden of Disease Study 2010［J］. Lancet，2012,380（9859）: 2163-2196.
［9］Martin S, Ljo H, Peuskens J, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months［J］. Curr Med Res Opin， 2002,18（6）:355-362.
［10］Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicenter,double-blind study (the Amisulpride Study Group)［J］. Eur Psychiatry，2000,15（5）:321-329.
［11］Peuskens J, Bech P, Moller HJ, et al. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group［J］. Psychiatry Res，1999,88（2）:107-117.
［12］Rzewuska M, Kuczyński W, Luks M. Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study［J］. Psychiatr Pol，2004，38(3):453-468.
［13］Loo H, Poirier-Littre MF, Theron M, et al. Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia［J］. Br J Psychiatry,1997,170:18-22.
［14］Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride［J］. Am J Psychiatry, 1999,156(4):610-616.
［15］Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride［J］. Br J Psychiatry, 1995,166(1):68-72.
［16］Leucht S, Pitschel-Walz G, Engel R, et al. Amisulpride-an unusual atypical antipsychotic. Ameta-analysis of randomized controlled trials［J］. Am J Psychiatry, 2002,159(2):180-190.
［17］Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia［J］. Drugs, 2001, 61(14):2123-2150.

[1]	李娜, 韩鸿璨, 王骏. 以药动学方法评价的抗精神分裂症药物人体生物等效性研究的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(12): 1419-1425.
[2]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[3]	张嘉萱, 邓顺顺, 邱玛丽, 杨双双. 利培酮单药或联合用药治疗后甲状腺激素水平的变化[J]. 中国临床药理学与治疗学, 2020, 25(10): 1145-1150.
[4]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[5]	胡德凤，王轶虎，龙小宇，王广水. 甘麦大枣汤加减方联合认知行为干预对精神分裂症超高危人群的干预作用及对认知功能、生活质量及血清5-HT、MT、TSH水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 546-553.
[6]	樊垚，薛永，汪昕，陈雪菲，张旭，姚应水，沈冲. 载脂蛋白E基因多态性与利培酮所致体质量降低的关联研究[J]. 中国临床药理学与治疗学, 2019, 24(3): 288-295.
[7]	蔡丹丹, 桂冬辉, 张建兵, 周文华. 小剂量利培酮联合曲唑酮应用于海洛因成瘾脱毒期的疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(1): 94-98.
[8]	曹婷，李娜娜，蔡骅琳. 神经甾体在精神分裂症发病与治疗中作用的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(6): 709-714.
[9]	崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.
[10]	陶怀, 魏钦令, 杨佳锦, 刘勇, 唐姝娟. 不同剂量帕潘立酮治疗对精神分裂症发育模型大鼠行为学的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 1001-1006.
[11]	杨艳，夏泳，朱长江，陈艳波. 阿立哌唑对氨磺必利所致高泌乳素血症的影响研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 693-696.
[12]	杭荣华, 李业平, 吴明飞, 李瑞. 门诊精神分裂症患者药物治疗的依从性与不良反应、社会支持的关系[J]. 中国临床药理学与治疗学, 2014, 19(8): 912-915.
[13]	倪平, 吕海龙, 国效峰, 张丽丽, 许林勇. 利培酮与奥氮平对精神分裂症急性期的疗效及临床影响因素的比较[J]. 中国临床药理学与治疗学, 2014, 19(2): 182-185.
[14]	钟智勇, 张明, 王继辉, 吴小立. 利培酮口服液与奥氮平治疗脑器质性精神障碍疗效与安全性分析[J]. 中国临床药理学与治疗学, 2012, 17(9): 1047-1051.
[15]	唐亚梅, 张向晖, 刘勇. 地佐环平诱导的精神分裂症发育模型大鼠脑组织去甲肾上腺素、5-羟色胺及代谢产物的浓度变化[J]. 中国临床药理学与治疗学, 2012, 17(7): 721-726.